[SERBADK] QoQ TTM Result on 31-Mar-2020

Stock
[SERBADK] SERBA DINAMIK HOLDINGS BERHAD
Announcement Date
20-May-2020
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2020
Quarter
31-Mar-2020
Profit Trend
QoQ- 4.34%
YoY- 27.2%
Quarter Report
Latest QR
Upcoming QR
SERBADK's Result
SERBADK's Financial Summary
View:
Show?
TTM Result
31/12/20 30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 CAGR
Revenue 6,014,075 5,558,976 5,122,159 4,822,902 4,528,620 4,146,069 3,871,228 33.95%
PBT 706,334 618,128 590,673 568,029 544,829 536,966 496,693 26.32%
Tax -74,247 -47,896 -54,756 -48,822 -46,845 -68,915 -60,435 14.63%
NP 632,087 570,232 535,917 519,207 497,984 468,051 436,258 27.89%
-
NP to SH 631,745 570,479 535,646 518,210 496,641 465,050 435,112 28.07%
-
Tax Rate 10.51% 7.75% 9.27% 8.59% 8.60% 12.83% 12.17% -
Total Cost 5,381,988 4,988,744 4,586,242 4,303,695 4,030,636 3,678,018 3,434,970 34.71%
-
Net Worth 3,301,565 3,166,196 3,068,136 2,513,358 1,548,501 2,364,285 2,261,489 28.54%
Dividend
31/12/20 30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 CAGR
Div 185,437 153,525 124,353 120,172 117,167 123,500 131,430 25.66%
Div Payout % 29.35% 26.91% 23.22% 23.19% 23.59% 26.56% 30.21% -
Equity
31/12/20 30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 CAGR
Net Worth 3,301,565 3,166,196 3,068,136 2,513,358 1,548,501 2,364,285 2,261,489 28.54%
NOSH 3,390,356 3,390,356 3,390,356 3,083,850 3,083,850 1,468,500 1,468,500 74.23%
Ratio Analysis
31/12/20 30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 CAGR
NP Margin 10.51% 10.26% 10.46% 10.77% 11.00% 11.29% 11.27% -
ROE 19.13% 18.02% 17.46% 20.62% 32.07% 19.67% 19.24% -
Per Share
31/12/20 30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 CAGR
RPS 162.12 165.04 151.92 157.35 231.04 282.33 263.62 -27.57%
EPS 17.03 16.94 15.89 16.91 25.34 31.67 29.63 -30.75%
DPS 5.00 4.56 3.69 3.92 5.98 8.41 8.95 -32.04%
NAPS 0.89 0.94 0.91 0.82 0.79 1.61 1.54 -30.50%
Adjusted Per Share Value based on latest NOSH - 3,083,850
31/12/20 30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 CAGR
RPS 161.36 149.15 137.43 129.40 121.50 111.24 103.86 33.96%
EPS 16.95 15.31 14.37 13.90 13.32 12.48 11.67 28.10%
DPS 4.98 4.12 3.34 3.22 3.14 3.31 3.53 25.65%
NAPS 0.8858 0.8495 0.8232 0.6743 0.4155 0.6343 0.6068 28.53%
Price Multiplier on Financial Quarter End Date
31/12/20 30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 CAGR
Date 31/12/20 30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 28/06/19 -
Price 1.76 1.64 1.65 1.50 2.20 4.25 4.03 -
P/RPS 1.09 0.99 1.09 0.95 0.95 1.51 1.53 -20.15%
P/EPS 10.33 9.68 10.39 8.87 8.68 13.42 13.60 -16.68%
EY 9.68 10.33 9.63 11.27 11.52 7.45 7.35 20.05%
DY 2.84 2.78 2.24 2.61 2.72 1.98 2.22 17.75%
P/NAPS 1.98 1.74 1.81 1.83 2.78 2.64 2.62 -16.96%
Price Multiplier on Announcement Date
31/12/20 30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 CAGR
Date 26/02/21 23/11/20 25/08/20 20/05/20 26/02/20 25/11/19 22/08/19 -
Price 1.71 1.70 1.73 1.79 2.34 4.30 4.39 -
P/RPS 1.05 1.03 1.14 1.14 1.01 1.52 1.67 -26.50%
P/EPS 10.04 10.04 10.89 10.59 9.24 13.58 14.82 -22.77%
EY 9.96 9.96 9.18 9.45 10.83 7.36 6.75 29.45%
DY 2.92 2.68 2.13 2.19 2.55 1.96 2.04 26.87%
P/NAPS 1.92 1.81 1.90 2.18 2.96 2.67 2.85 -23.05%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment